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Abstract 
Background: Hair diseases place an important burden on patients’ l ves, causing significant 
emotional and psychosocial distress. However, the impairment due to different hair 
conditions, such as alopecia areata (AA) and androgenetic alopecia (AGA), has rarely been 
compared.  
 
Objective: The aim of this study was to assess the psychological burden of sub-groups of 
patients with different hair diseases and to compare them to a healthy population.   
 
Methods: This study is part of a large multicenter study including 3635 adult dermatological 
out-patients and 1359 controls from 13 European countries.  
In the sub-group of patients with hair diseases, we analyzed the sociodemographic 
characteristics, the stress level, and the impact of hair diseases on quality of life (QoL), 
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anxiety, and depression and we compared them among patients with AA, AGA, and healthy 
controls.  
 
Results: The study population included 115 patients (77% women, 23% men) with hair 
diseases. Patients with hair diseases had a lower education level than healthy controls 
(medium educational level: 43% vs 28%). Overall, 41% of the patients reported stressful life 
events during the last 6 months compared with 31% of the controls. Patients with the same 
age, sex, depression level and comorbidities had a worse QoL when suffering from AA than 
from AGA (Mean DLQI score: 5,8 vs 2,5). 
 
Conclusion: Patients with hair diseases are more anxious, depressed and have a worse QoL 
than controls. These results suggest that a psychotherapeutic and psychopharmacological 
approach should be proposed when necessary. 
 
INTRODUCTION: 
 
In humans, hair is predominantly considered as an aesthetic concern, however hair diseases 
may lead to an important burden on patients’ li ves, causing significant emotional and 
psychosocial distress (1).  The most common hair diseases are alopecia areata (AA) and 
alopecia androgenetica (AGA). 
It has been observed that AA significantly reduces patients’ quality of life (QoL) (2). In 
addition, AA patients have a high prevalence of psychiatric comorbidities, such as anxiety, 
depression, social phobia, and personality disorders (3, 4). It is therefore difficult to know to 
what extent the impact of this impairment is, comparable to other skin diseases.  
In an Indian study of alopecia with a wide range of etiologies including chemotherapy related 
alopecia, Sellami et al have shown that alopecia patients were more anxious and depressed 
than controls (5). In 50 AA patients, 62% had symptoms of anxiety and 38% of depression 
(5). These percentages were significantly higher than in the control group. In patients with 
AGA a significant impact on QoL was found, particularly when associated with high severity, 
a longer duration, younger age, having received previous non-medical hair care, and hospital 
visits for AGA treatment (6).  
Compared to other skin conditions, which may be accompanied by itching, pain or other 
sensations that provide distinctive symptoms, in most hair diseases the patients generally only 
experience the symptom of “hair loss”  Considering this mono-symptomatic aspect of hair 
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diseases, it is interesting to investigate other associated aspects that may differentiate the 
impact of different hair diseases (AA, AGA, other diseases). 
The aim of this study was to assess the psychological burden of patients with hair diseases in 
a large European sample. For this purpose, we compared different subgroups of patients with 
hair diseases with a healthy control population, regarding the level of anxiety, depression, 
stress, and QoL impairment.  
 
 
 
 
 METHODS: 
 
Study population 
A multicenter, observational, case-control study was conducted in 13 European countries. The 
details have been described previously (7). In brief, in the dermatology clinics of each 
country, all patients with dermatological diseases were consecutively recruited. Controls were 
recruited in all centers among the hospital staff who did not currently have or previously had 
any dermatological disorder. Both cases and controls had to complete questionnaires on QoL 
and psychological comorbidities.  Data were complete for 3635 patients and 1359 controls. In 
the present study, we have included patients with hair diseases and healthy controls.  
 
Questionnaires 
The first part of the questionnaire recorded socio-demographic variables including age, 
gender, marital status, and self-reported socio-economic status. Ethnicity was self-reported by 
each participant referring to their own country of birth.  
 
The presence of symptoms of depression and anxiety was assessed with the HADS, a well-
validated instrument showing good psychometric properties, aimed to assess symptoms of 
anxiety disorders and depression in somatic, psychiatric, and primary care patients, as well as 
in the general population. HADS includes seven items assessing anxiety and seven assessing 
depression, each with four possible answers. For each dimension of anxiety and depression a 
score from 0 to 7 is considered normal, from 8 to 10 a borderline case, and from 11 to 21 a 
case in need of further examination or treatment. This instrument was used in the validated 
translations relevant to the study countries. 
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To assess health related quality of life (HRQoL), we used two different self-rated 
questionnaires: the Dermatology Life Quality Index (DLQI) and the EQ-5D-3L. The DLQI is 
a dermatological specific, ten-item questionnaire used to measure the impact of skin disease 
on the QoL of an affected person. The ten questions cover the following topics: symptoms, 
embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, 
close relationships, sex and treatment. Each question is scored from 0 to 3, giving a possible 
total score range from 0 (no impact of skin disease on QoL) to 30 (maximum impact on QoL). 
The EQ-5D-3L essentially consists of 2 parts: the EQ-5D descriptive system and the EQ 
visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 
5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 
Each dimension has three levels: no problems, some problems, extreme problems. The 
respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box 
against the most appropriate statement in each of the 5 dimensions. The EQ VAS records the 
respondent’s self-rated health on a vertical, visual analogue 100-degree scale (0= “worst 
imaginable health state”; 100= “best imaginable health state”). 
This information can be used as a quantitative measure of health outcome as judged by the 
individual respondents. Stress was assessed with the item “Have you had any stressful life 
event during the last 6 months?” (yes/no). 
 
Patients completed all the questionnaires, while controls did not complete the DLQI.  
 
Statistical analysis: 
Analyses were performed with R version 3.1.0. Baseline characteristics were compared 
between groups (controls versus any hair diseases; controls versus AA and AGA; men versus 
women; different age groups) by Fisher’s exact tests for categorical variables and t-tests or 
ANOVA for continuous variables (or Wilcoxon tests if needed). The categorical scores were 
compared by Fisher’s exact tests between groups. The DLQI scores and EQ5D scores, 
considered on continuous scales, were also compared (separately) by multivariate regressions 
after a logarithmic transformation for DLQI (to fulfill the normality assumption) with the 
groups, age, sex, depression and comorbidities as predictors (adjusting variables). The HADS 
scores, considered on a continuous scale, were compared between groups with t-tests or 
ANOVA (the normality assumption has been checked with QQ plot). The EQ5D scores were 
compared by Wilcoxon tests, or Kruskal-Wallis non-parametric ANOVA between gender and 
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categorized age, while their five components were compared by Fisher’s exact tests. The 
population was adjusted by linear model for age, sex, depression and comorbidities. Some 
results are presented using box-plots which are a convenient way of graphically depicting 
groups of numerical data through their quartiles. Box plots may have lines extending 
vertically from the boxes (whiskers) indicating variability outside the upper and lower 
quartiles, hence the terms box-and-whisker plot and box-and-whisker diagram.  
RESULTS: 
Details of participants’ characteristics have been previously published (7). In this study, we 
included 115 patients with hair diseases and 1359 controls. In the group of patients with hair 
diseases, there were 37 patients with AA, 20 patients with AGA, and 58 patients with other 
hair conditions such as lichen planus of the scalp, telogen effluvium, cicatricial alopecia, 
frontal fibrosing alopecia and others.  
 
Table 1 shows a comparison between the characteristics of the hair diseases group and the 
controls. In the hair diseases group, there were more females than in the control group; 46% 
of the patients were educated to a medium education level (i.e., primary or secondary school) 
compared with 28% of the controls. Finally, tertiary (university) level education was achieved 
by a smaller proportion of patients than controls (29% vs 43%).  
Comparing subgroups of patients with hair diseases, we observed that AA and the subgroup 
of other hair diseases were more likely to have achieved a medium level education than AGA 
patients (47% and 49%, respectively, vs. 35%), (p=0.007). A higher proportion of AA 
patients were married  (70%) compared to the other hair disease population (49%), (p=0.021). 
Stress was reported by 49% of the AA patients and 35% of the AGA and 31% of controls 
(p=0.061). 
HADS mean score in patients (anxiety 7.9; depression 5.4) was significantly higher compared 
to controls (anxiety 5.6; depression 3.6). Overall, 41% of the patients reported stressful life 
events during the last 6 months compared with 31% of the controls. 
Patients with same age, sex and comorbidities had a higher DLQI score when suffering from 
AA than AGA, (Fig. 1). Figure 2 (Fig. 2) shows that patients with AA had a higher HADS 
score compared to the AGA population. An ANOVA Test was performed to compare 
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controls, AA and AGA population and confirmed the results above. (Anxiety p<0.001; 
depression p=0.005).  
Females had a poorer quality of life (Fig. 3a), especially in the pain dimension (p=0.001) and 
anxiety and depression dimension (p=0.012). Patients aged more than 50 years old had lower 
EQ-5D scores (p<0.001) and EQ VAS scores (Fig. 3b), i.e. a more impaired QoL, than 
younger patients.  
 Comparison between controls, AA and AGA patients showed a lower EQ-5D score in both 
AA and AGA patients when adjusted for age, sex, depression and comorbidities (Fig. 3c). 
Specifically, EQ-5D activity, pain and anxiety and depression dimensions showed lower 
scores in all hair patients compared to controls (p=0.002, p<0.001, p<0.001). Also, EQ VAS 
score was lower for all hair patients compared to controls when adjusted for age, sex, 
depression and comorbidities. AA patients reported lower self-evaluated health than AGA 
patients and controls when using the EQ VAS scale (fig. 3d) and had a lower EQ-5D anxiety 
and depression scores (p<0.001). All other comparisons did not show any significant 
differences. 
 
DISCUSSION: 
 
How do hair diseases affect patients’ lives? In this study, we found that having any hair 
disease was associated with more anxiety, a more depressed mood and impaired QoL 
compared to a control group without skin disease. These differences were most pronounced in 
AA patients. 
The special impact of AA is in line with previous studies. Liu et al. showed that HRQoL 
experienced by patients with AA is similar to that seen in patients with other chronic skin 
diseases including atopic dermatitis and psoriasis (8, 9). Rencz et al. have also demonstrated 
that patients with AA experience significant impairment in HRQoL, especially in the area of 
mental health (2).  
AA patients may suffer more than patients affected by other hair diseases for different 
reasons. AA is a chronic disease and is well known for having a significant impact on the 
psychological sphere of patients. Indeed, AA is a burdensome medical problem because 
concealing the symptoms of that condition is relatively difficult, especially for women. T. 
Cartwright showed that QoL was significantly poorer for women with alopecia, compared 
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with men. There were gender differences in several of the DLQI subscales. Women were 
significantly more likely to feel that alopecia affected their leisure activities and personal 
relationships, while men scored higher on work interference than women (10). 
 
AA also has a major impact on the social life of a patient, leading him/her to feel socially 
alienated and rejected. Furthermore, AA is associated with mental disorders such as 
depression, anxiety disorders, body dysmorphic disorders, social phobia and suicidal 
thoughts. These mental disorders could be primary conditions which declare themselves in 
medical problems associated with the skin or these could be a result of this serious and 
disfiguring condition (11).  
An interesting result was the significant difference of marital status between the AA patients 
and other hair disease patients. In fact, 70% of AA patients were in a relationship compared to 
49% of the others. In a previous study, we demonstrated that there are more dysfunctional 
families in AA patients (12). Those dysfunctions could be fusions and ruptures, generational 
repetition of behaviors of dependence or vulnerability and unsolved mourning if traumatic 
events are experienced. We could hypothesize that not resolving these problems could lead to 
increasing the perceived stress and consequently to more anxiety and depression. Moreover, 
these patients have a lower education level, which is usually correlated with earlier 
partnerships  (13,14). Further studies should be done to confirm this hypothesis. 
 
Concerning the AGA patients, we also found an impact on HRQoL. Their level of anxiety and 
depression was also higher than for the controls. In previous studies, it has been shown that 
the HRQoL of male and female AGA patients is altered, in particular in younger patients 
(6,13,15). This should not be underestimated and psychological support could be helpful for 
these patients. 
  
The weakness of this study is that several generic and dermatology-specific HRQoL 
instruments have been used, but no specific instruments for AA were used. The newly 
developed AA-specific measures seem very promising, however, a more extensive assessment 
of validity and reliability is needed. 
 
In conclusion, patients with hair diseases experience a considerable impact on their QoL and 
may benefit from a psychological assessment. We recommend the use of anxiety and 
depression questionnaires such as HADS, which is specific and user-friendly. Some caution 
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remains warranted: we must take into account the risk of biases such as underestimation with 
self-administered questionnaires; moreover AA patients are often alexithymic (16) and 
therefore have problems in articulating their affections. We therefore recommend letting the 
patient complete the questionnaire on his own and evaluate the answers with the 
dermatologist. Also, the observation of patients’ nonverbal behavior is an invaluable tool to 
assess the presence of depression. Finally, once an adequate psychological assessment has 
been performed, psychotherapeutic and psychopharmacological support should be offered to 
patients whenever such support appears to be conducive to a better outcome. 
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Table 1: Comparison between hair diseases groups and controls. Mean values given with 
standard deviation (SD) 
 
VARIABLE LEVEL N (%) Hair diseases  N (%) controls P-value 
Sex Male  27 (23%) 453 (33%) P=0,03 
 Female 88 (77%) 903 (67%)  
     
Educational level Medium 49 (46%) 375 ( 28%) P<0,001 
 High 26 (25%) 399 (30%)  
 University 31 (29%) 577 (43%)  
 
Stressful life events 
reported during the 
last 6 months 
 47 (41%) 412 (31%) P=0,02 
     
  Mean values (SD) Mean values (SD) P-value 
Age  41.6 (SD) 41.1 (SD) P=0,732 
HADS Anxiety 
HADS Depression 
 7.9 (SD) 
5.4 (SD) 
5.6 (SD) 
3.6 (SD) 
P<0,001 
P<0,001 
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  Median  Median  
EQ-5D  0.8 1 P<0,001 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Median scores of quality of life as assessed with the DLQI in alopecia areata (AA) 
and androgenetic alopecia (AGA) (p= 0,022) 
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Figure 2: Score of Anxiety and Depression (HADS) in Control - AA–AGA patients (Anxiety 
p< 0,001; depression p=0,02) 
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Figures 3a: Median scores for Health Related Quality of Life (HRQoL) as assessed by the 
(EQ5D) in male versus female patients (p=0,001) 
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Figure 3b: HRQoL as assessed by the EQ5D in different age groups  (p<0.001) 
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Figure 3c: HRQoL in general health  (EQ5D) in control- AA-AGA patients (p=0,003) 
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Figure 3d: HRQoL with visual analogue score (EQ VAS) in control - AA AGA patients  
(p<0,001) 
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